Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by nomoneyon Jul 26, 2019 7:00pm
126 Views
Post# 29966106

RE:RE:News

RE:RE:News

Pursuant to the proposed Transaction, the holders of the issued and outstanding MMED Shares shall receive one post-Consolidation (as defined below) Broadway common share for each MMED common share held. As well, Broadway has agreed to seek shareholder approval for, among other things: (i) the consolidation of its outstanding shares, warrants and options on an eight (8) old share for one (1) new share basis (the "Consolidation"); (ii) the change of name of Broadway to "Mind Medicine, Inc." or such other name as MMED may determine (the "Name Change"); and (iii) subject to TSX Venture Exchange approval, the spin-out to Broadway's existing shareholders of all of the mining assets related to its Broadway and Madison mine and the Tsumeb land package in Namibia (the "Spin-out").

The Spin-out will be effected by way of contingent dividend or other mechanism deemed to be the most effective for tax and corporate law purposes, payable to Broadway's existing shareholders following completion of the proposed Transaction. The dividend will be paid in-kind by the distribution of shares of a subsidiary corporation ("Spin-Co") holding all the issued shares of Broadway's wholly-owned Montana subsidiary Broadway Gold Corp. and the Tsumeb land package in Namibia. Spin-Co is not expected to seek a concurrent listing of these shares on any stock exchange.

Bullboard Posts